Welcome to our dedicated page for Aegon Nv SEC filings (Ticker: AEGOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aegon Nv's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aegon Nv's regulatory disclosures and financial reporting.
BlackRock, Inc. reported beneficial ownership of 107,463,526 shares of AEGON LTD common stock, equal to 6.8% of the class, in an amended Schedule 13G/A. The filing shows sole voting power for 101,605,542 shares and sole dispositive power for 107,463,526 shares, with the position reflected as of 03/31/2026.
BlackRock, Inc. reported beneficial ownership of 107,463,526 shares of AEGON LTD common stock, equal to 6.8% of the class, in an amended Schedule 13G/A. The filing shows sole voting power for 101,605,542 shares and sole dispositive power for 107,463,526 shares, with the position reflected as of 03/31/2026.
Aegon Ltd plans to sell Aegon UK to Standard Life for total consideration of GBP 2.0 billion. The deal consists of a 15.3% shareholding in Standard Life, equal to 181.1 million shares, plus GBP 0.75 billion in cash, adjusted for any remittances from Aegon UK before closing.
The price equates to 14.2 times Aegon UK’s 2025 operating result after tax and 1.9 times its 2025 IFRS shareholder’s equity. Aegon expects to use the net cash proceeds for a mix of deleveraging and share buybacks once the transaction is completed. On a pro forma 2025 basis, the sale is expected to add EUR 1.1 billion to group shareholders’ equity and EUR 0.6 billion to group net result, while reducing the Group Solvency ratio by 5 percentage points.
Following closing, Aegon’s 2026–2027 financial guidance will be updated, with target growth rates unchanged but based on adjusted run-rates, including a EUR 1.3–1.5 billion group operating result run-rate and EUR 0.7–0.75 billion Operating Capital Generation in 2025 terms. Aegon will retain its UK asset management activities and will hold a board seat at Standard Life, with a lock-up on the new shares lasting until the earlier of 18 months after completion or completion of Aegon’s planned redomiciliation to the United States.
Aegon Ltd plans to sell Aegon UK to Standard Life for total consideration of GBP 2.0 billion. The deal consists of a 15.3% shareholding in Standard Life, equal to 181.1 million shares, plus GBP 0.75 billion in cash, adjusted for any remittances from Aegon UK before closing.
The price equates to 14.2 times Aegon UK’s 2025 operating result after tax and 1.9 times its 2025 IFRS shareholder’s equity. Aegon expects to use the net cash proceeds for a mix of deleveraging and share buybacks once the transaction is completed. On a pro forma 2025 basis, the sale is expected to add EUR 1.1 billion to group shareholders’ equity and EUR 0.6 billion to group net result, while reducing the Group Solvency ratio by 5 percentage points.
Following closing, Aegon’s 2026–2027 financial guidance will be updated, with target growth rates unchanged but based on adjusted run-rates, including a EUR 1.3–1.5 billion group operating result run-rate and EUR 0.7–0.75 billion Operating Capital Generation in 2025 terms. Aegon will retain its UK asset management activities and will hold a board seat at Standard Life, with a lock-up on the new shares lasting until the earlier of 18 months after completion or completion of Aegon’s planned redomiciliation to the United States.
AEGON LTD. Chief Financial Officer Russell Duncan James reported a tax-related share transfer. He used 59,926 Common Shares on a Form 4/A as a tax-withholding disposition at $7.1512 per share to satisfy tax obligations, rather than an open-market sale. Following this transaction, he directly holds 462,972 Common Shares.
AEGON LTD. Chief Financial Officer Russell Duncan James reported a tax-related share transfer. He used 59,926 Common Shares on a Form 4/A as a tax-withholding disposition at $7.1512 per share to satisfy tax obligations, rather than an open-market sale. Following this transaction, he directly holds 462,972 Common Shares.
Aegon Ltd plans to ask shareholders to extend CEO Lard Friese’s term at its Annual General Meeting on June 10, 2026. The Board of Directors will propose keeping him as Executive Director and Chief Executive Officer until 2030, instead of his current term ending at the 2028 AGM.
Chairman David Herzog highlights Friese’s leadership as central to Aegon’s transformation, including its planned relocation of legal domicile and head office to the United States and its ambition to become a leading US life insurance and retirement group. The company notes the proposal aims to support leadership continuity while it continues executing its strategy.
Aegon Ltd plans to ask shareholders to extend CEO Lard Friese’s term at its Annual General Meeting on June 10, 2026. The Board of Directors will propose keeping him as Executive Director and Chief Executive Officer until 2030, instead of his current term ending at the 2028 AGM.
Chairman David Herzog highlights Friese’s leadership as central to Aegon’s transformation, including its planned relocation of legal domicile and head office to the United States and its ambition to become a leading US life insurance and retirement group. The company notes the proposal aims to support leadership continuity while it continues executing its strategy.
Aegon Ltd. has filed Amendment No. 1 to its Form 20-F for the year ended December 31, 2025 to add audited financial statements of ASR Nederland N.V. prepared under IFRS as adopted by the EU. Aegon holds a less than 50% non-controlling interest in ASR and accounts for it using the equity method.
The amendment is required under Rule 3-09 of Regulation S-X because ASR met the significant subsidiary test for 2024, so the filing now includes ASR’s 2025 audited financials with 2024 comparatives, the related KPMG audit report, KPMG’s consent, and updated CEO and CFO certifications. No other parts of the original 2025 Form 20-F are revised.
Aegon Ltd. has filed Amendment No. 1 to its Form 20-F for the year ended December 31, 2025 to add audited financial statements of ASR Nederland N.V. prepared under IFRS as adopted by the EU. Aegon holds a less than 50% non-controlling interest in ASR and accounts for it using the equity method.
The amendment is required under Rule 3-09 of Regulation S-X because ASR met the significant subsidiary test for 2024, so the filing now includes ASR’s 2025 audited financials with 2024 comparatives, the related KPMG audit report, KPMG’s consent, and updated CEO and CFO certifications. No other parts of the original 2025 Form 20-F are revised.
AEGON LTD. Chief Financial Officer Russell Duncan James reported a Form 4 transaction where 61,678 Common Shares were disposed of at $7.1512 per share to satisfy tax obligations through share withholding. This was a non-open-market, tax-withholding disposition rather than a discretionary sale. Following the transaction, he directly holds 461,220 Common Shares.
AEGON LTD. Chief Financial Officer Russell Duncan James reported a Form 4 transaction where 61,678 Common Shares were disposed of at $7.1512 per share to satisfy tax obligations through share withholding. This was a non-open-market, tax-withholding disposition rather than a discretionary sale. Following the transaction, he directly holds 461,220 Common Shares.
AEGON LTD. director Thomas Peter Wellauer reported a routine tax-related share disposition. On March 25, 2026, 2,632 common shares were delivered at an implied price of $7.1512 per share to satisfy tax obligations. After this tax-withholding transaction, he directly holds 11,215 common shares.
AEGON LTD. director Thomas Peter Wellauer reported a routine tax-related share disposition. On March 25, 2026, 2,632 common shares were delivered at an implied price of $7.1512 per share to satisfy tax obligations. After this tax-withholding transaction, he directly holds 11,215 common shares.
AEGON LTD. Chief Executive Officer Eilard Friese reported a disposition of 100,521 common shares on March 25, 2026 to satisfy tax obligations by delivering shares. This tax-withholding event was not an open-market trade. After the transaction, he directly held 612,817 common shares.
AEGON LTD. Chief Executive Officer Eilard Friese reported a disposition of 100,521 common shares on March 25, 2026 to satisfy tax obligations by delivering shares. This tax-withholding event was not an open-market trade. After the transaction, he directly held 612,817 common shares.
Aegon Ltd. reports a stronger 2025 and sets out a clearer, US‑centered strategy. Operating result rose 15% year-on-year to EUR 1.7 billion, supported by growth across units and better experience variances. Operating capital generation before holding and funding expenses reached EUR 1.3 billion, while free cash flow was EUR 829 million and Cash Capital at Holding stood at EUR 1.3 billion.
The group sharpened its focus on Transamerica, which now represents about 70% of operations, and aims to become a leading US life insurance and retirement group. It plans to relocate its head office and legal seat to the US, ultimately rename the holding company Transamerica Inc., and transition reporting from IFRS to US GAAP for full‑year 2027, targeting domestic issuer status in the US by January 1, 2028. Aegon reduced its strategic shareholding in a Dutch insurance company to roughly 24%, raising gross proceeds of EUR 700 million, and continues to emphasize financial empowerment, sustainability, and responsible investing across its international insurance and asset management businesses.
Aegon Ltd. reports a stronger 2025 and sets out a clearer, US‑centered strategy. Operating result rose 15% year-on-year to EUR 1.7 billion, supported by growth across units and better experience variances. Operating capital generation before holding and funding expenses reached EUR 1.3 billion, while free cash flow was EUR 829 million and Cash Capital at Holding stood at EUR 1.3 billion.
The group sharpened its focus on Transamerica, which now represents about 70% of operations, and aims to become a leading US life insurance and retirement group. It plans to relocate its head office and legal seat to the US, ultimately rename the holding company Transamerica Inc., and transition reporting from IFRS to US GAAP for full‑year 2027, targeting domestic issuer status in the US by January 1, 2028. Aegon reduced its strategic shareholding in a Dutch insurance company to roughly 24%, raising gross proceeds of EUR 700 million, and continues to emphasize financial empowerment, sustainability, and responsible investing across its international insurance and asset management businesses.
AEGON LTD. director Caroline Frances Ramsay has reported ownership of 13,229 Common Shares. This position includes 9,854 Common Shares that are subject to time-based vesting in line with the applicable grant agreements, indicating that a substantial portion of her holding will vest over time.
AEGON LTD. director Caroline Frances Ramsay has reported ownership of 13,229 Common Shares. This position includes 9,854 Common Shares that are subject to time-based vesting in line with the applicable grant agreements, indicating that a substantial portion of her holding will vest over time.